跳至主要内容
临床试验/NCT02749513
NCT02749513Unknown早期 1 期

Feasibility of Itraconazole as a Targeted Therapy for Inhibition of Hedgehog Pathway Signaling in Patients With Esophageal Cancer

Dallas VA Medical Center1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2016年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
入组人数
18
试验地点
1
主要终点
Inhibition of Hedgehog pathway signaling as measured by real-time PCR.

研究概览

简要总结

The purpose of this study is to demonstrate that orally administered itraconazole, a commonly used antifungal medication, can inhibit Hedgehog pathway signaling in patients with esophageal cancer, including adenocarcinoma (EAC) and squamous cell carcinoma (ESCC).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinical diagnosis of esophageal cancer, including gastroesophageal junction cancer

排除标准

  • Patients unwilling or unable to provide informed consent
  • Coagulopathy that precludes safe endoscopic/surgical procedure (platelet count <100,000/mm3, INR>1.5)
  • Esophageal varices
  • Comorbidity (e.g. pulmonary, cardiac, renal, or liver disease) that precludes safe participation in the study
  • QTc>450 ms
  • LFT's>3xULN
  • Pregnancy
  • Allergy to itraconazole
  • History of symptomatic congestive heart failure

研究组 & 干预措施

Itraconazole

Experimental

Itraconazole 300 mg po bid for 14-17 days

干预措施: Itraconazole (Drug)

结局指标

主要结局

Inhibition of Hedgehog pathway signaling as measured by real-time PCR.

时间窗: 2-3 weeks

mRNA expression levels as measured by real-time PCR of Hedgehog pathway ligands and target genes will be compared between baseline and post-itraconazole treatment.

次要结局

  • Inhibition of VEGFR2 pathway signaling as measured by Western blot(2-3 weeks)

研究者

申办方类型
Fed
责任方
Principal Investigator
主要研究者

David Wang

Staff Physician, Hematology-Oncology

Dallas VA Medical Center

研究点 (1)

Loading locations...

相似试验